Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage radiotherapeutics company focused on developing a pipeline of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to transform cancer care by delivering innovative solutions for earlier detection and personalized treatment of cancers with unmet needs.
Short position
Radiopharm Theranostics (ASX:RAD) has 1.27% of its shares on issue reported as short positions as of 16 Sept 2026, or about 54,932,710 shares. Over the past 30 days that figure has risen 1.25 percentage points, and over 90 days it has risen 1.22 percentage points. RAD is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Radiopharm Theranostics (RAD) company profile
Profile, insiders and operations
Company
AI-generated research profile of Radiopharm Theranostics
RAD intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links